Article

Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK

2021-09-21

Abstract excerpt

<h4>Background</h4> COVID-19 vaccines have been used for 9 months in the UK. Real world data have demonstrated the vaccines to be highly effective against COVID-19, severe disease and death. Here, we estimate vaccine effectiveness over time since the second dose of Comirnaty, Vaxzevria and Spikevax in England. <h4>Methods</h4> We used a test-negative case-control design to estimate vaccine effectiveness against sy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8528c485-8746-51ab-8680-d979ba4ce697
DOI: 10.1101/2021.09.15.21263583

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UKDOI 10.1101/2021.09.15.21263583Read

Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccinesSemantic proximity Read

Comparative effectiveness of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaignSemantic proximity Read

The Effectiveness of COVID-19 Vaccination in a Regional PopulationSemantic proximity Read

Cohort profile: an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands – The VAccine Study COvid-19 (VASCO)Semantic proximity Read

Vaccine effectiveness and duration of protection against symptomatic and severe Covid-19 during the first year of vaccination in FranceSemantic proximity Read

Neutralising antibodies predict protection from severe COVID-19Semantic proximity Read

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control studySemantic proximity Read

Waning effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccines over six months since second dose: a cohort study using linked electronic health recordsSemantic proximity Read

Effectiveness of Mrna Booster Vaccination Against Mild and Severe COVID-19 During Delta and Omicron Variant Circulation in Germany: An Analysis of National Surveillance DataSemantic proximity Read

Prediction of Covid-19 vaccine effectiveness in adult populations and in clinically-vulnerable subgroupsSemantic proximity Read

Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in EnglandSemantic proximity Read

Durability of protection post-primary COVID-19 vaccination in the US: matched case-control studySemantic proximity Read